Gland Pharma shares reached a new 52-week high after the company reported strong results for the March quarter and full year. The European unit Cenexi showed signs of recovery while new product launches and capacity additions supported the outlook.
Gland Pharma stock climbed to its highest level in a year following the release of robust quarterly and annual figures. The company highlighted improving profitability at its European subsidiary Cenexi as a key positive factor.
ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.
Reported by AI
Indian fund managers directed fresh investments into pharmaceutical and non-banking financial companies during April. The moves targeted defensive stocks amid concerns over oil prices and tensions in West Asia.
Germany's DAX index hit 24,260 points intraday on Thursday, its highest level in six weeks, closing at 24,154 points up 0.4 percent. Investors are optimistic amid hopes for an end to Middle East hostilities between Iran and the US. The S&P 500, Nikkei, and MSCI World also reached records.
Reported by AI
Multi Commodity Exchange of India posted a sharp rise in earnings for the quarter ended March. Consolidated net profit reached 530 crore rupees, up 291 percent from the prior year. The exchange also announced a dividend of 8 rupees per share.